“More efficient clinical trials translate to reduced barriers to market for safe, innovative medicines, which is the ultimate goal of patients and manufacturers alike”- this statement from a recent article posted on BIO’s website speaks the truth. This is what we’re all after, but the question remains; how do we get there?